Barclays’s Celldex Therapeutics CLDX Stock Holding History

Barclays’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,867	Closed	-$205K	–	6994
2018 Q1	$205K	Buy	+5,867	New	+$227K	﹤0.01%	4810
2015 Q2	–	Sell	-1,713	Closed	-$694K	–	7027
2015 Q1	$694K	Sell	1,713 -3,434	-67%	-$1.23M	﹤0.01%	3296
2014 Q4	$1.39M	Buy	+5,147	New	+$1.28M	﹤0.01%	2874
2014 Q1	–	Sell	-8,333	Closed	-$3M	–	7578
2013 Q4	$3M	Buy	8,333 +4,293	+106%	+$1.65M	﹤0.01%	2268
2013 Q3	$2.12M	Buy	+4,040	New	+$1.39M	﹤0.01%	2504

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's CLDX Position: Q2 2026 in Review

Barclays increased its Celldex Therapeutics (CLDX) stake by 8% in Q2 2026, buying an estimated $35.9K and bringing the position to 15,087 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

Barclays first reported a position in CLDX in Q2 2013 and has held it in 50 quarters since. The position peaked at $7.04M in Q1 2022. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Barclays held 15,087 shares of Celldex Therapeutics worth $561K as of Q2 2026.
Barclays bought 1,112 Celldex Therapeutics shares in Q2 2026, an estimated $35.9K.
Celldex Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3145 holding.
Barclays first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 50 quarters since.
Barclays's Celldex Therapeutics position peaked at $7.04M in Q1 2022.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.